Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus–Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial
John V. Hegde(UCLA Health), Allen M. Chen(University of California, Davis), Pin‐Chieh Wang(University of California, Los Angeles), Jonathan W. Riess(University of California Davis Medical Center), Darlene Veruttipong(University of California, Los Angeles), Sophia Hsu, Shyam Rao(University of California, Davis), Narek Shaverdian(University of Wisconsin–Madison), Carol Felix(University of California, Los Angeles), Megan E. Daly(University of California Davis Medical Center)
International Journal of Radiation Oncology*Biology*Physics
November 6, 2017
Cited by 14
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670